Skip to main content

Table 1 Studies comparing IC and IV administration of abciximab in patients with STEMI

From: Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration

Author

Year*

Design

Patients

No

In favor of

Main results

Wohrle et al [34]

2003

retrospective

STEMI/NSTEACS

403

IC

reduced incidence of MACE at 30 days

Bellandi et al [27]

2004

prospective, randomized

STEMI

45

IC

higher salvage index and LV functional recovery (serial gated SPECT)

Romagnoli et al [32]

2005

prospective, matched

STEMI/NSTEACS

74

IC

increased coronary flow (cTFC)

Galache et al [29]

2006

prospective, randomized

STEMI/NSTEACS

137

neutral

no difference in the incidence of MACE at 1 year

Thiele et al [33]

2008

prospective, randomized

STEMI

154

IC

reduced infarct size and extent of MO (MRI at 2 days)

Dominguez-Rodriguez et al [28]

2009

prospective, randomized

STEMI

50

IC

larger reduction in soluble CD40 ligand

  1. * Year of publication
  2. cTFC: corrected TIMI frame count; IC: intracoronary; IV: intravenous; MACE: major adverse cardiac event; MO: microvascular obstruction; MRI: magnetic resonance imaging; No: number of patients; NSTEACS: non-ST-elevation acute coronary syndrome; SPECT: single photon emission computed tomography; STEMI: ST-segment elevation myocardial infarction